L. Ha, T. Ichikawa, M. Anver, R. Dickins, S. Lowe et al., ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence, Proc Natl Acad Sci U S A, vol.104, pp.10968-10973, 2007.

L. Ha, G. Merlino, and E. V. Sviderskaya, Melanomagenesis: overcoming the barrier of melanocyte senescence, Cell Cycle, vol.7, pp.1944-1948, 2008.

S. Haferkamp, T. M. Becker, L. L. Scurr, R. F. Kefford, R. et al., p16INK4a-induced senescence is disabled by melanoma-associated mutations, Aging Cell, vol.7, pp.733-745, 2008.

L. Hayflick and P. S. Moorhead, The serial cultivation of human diploid cell strains, Exp Cell Res, vol.25, pp.585-621, 1961.

J. Y. Heo, K. Jing, K. S. Song, K. S. Seo, J. H. Park et al., Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells, Stem Cells, vol.27, pp.1455-1462, 2009.

Y. Hirose, M. S. Berger, and R. O. Pieper, p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res, vol.61, pp.1957-1963, 2001.

J. S. Ho, W. Ma, D. Y. Mao, and S. Benchimol, p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest, Mol Cell Biol, vol.25, pp.7423-7431, 2005.

K. Hoek, D. L. Rimm, K. R. Williams, H. Zhao, S. Ariyan et al., Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas, Cancer Res, vol.64, pp.5270-5282, 2004.

A. Ismail and A. Bateman, Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma, Cancer Lett, vol.278, pp.230-240, 2009.

J. J. Jacobs, P. Keblusek, E. Robanus-maandag, P. Kristel, M. Lingbeek et al., Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers, Nat Genet, vol.26, pp.291-299, 2000.

J. Jane-valbuena, H. R. Widlund, S. Perner, L. A. Johnson, A. C. Dibner et al., An oncogenic role for ETV1 in melanoma, Cancer Res, vol.70, pp.2075-2084, 2010.

R. Jones, M. Ruas, F. Gregory, S. Moulin, D. Delia et al., A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6, Cancer Res, vol.67, pp.9134-9141, 2007.

T. Kamijo, F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing et al., Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF, Cell, vol.91, pp.649-659, 1997.

C. Kannengiesser, S. Brookes, A. G. Del-arroyo, D. Pham, J. Bombled et al.,

O. Mauffret, M. F. Avril, A. Chompret, and G. M. Lenoir, Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00539303

N. M. Mhaidat, X. D. Zhang, J. Allen, K. A. Avery-kiejda, R. J. Scott et al., , 2007.

, Temozolomide induces senescence but not apoptosis in human melanoma cells, Br J Cancer, vol.97, pp.1225-1233

C. Michaloglou, L. C. Vredeveld, W. J. Mooi, and D. S. Peeper, BRAF(E600) in benign and malignant human tumours, Oncogene, vol.27, pp.877-895, 2008.

C. Michaloglou, L. C. Vredeveld, M. S. Soengas, C. Denoyelle, T. Kuilman et al., BRAFE600-associated senescence-like cell cycle arrest of human naevi, Nature, vol.436, pp.720-724, 2005.

P. J. Mishra, L. Ha, J. Rieker, E. V. Sviderskaya, D. C. Bennett et al.,

G. Merlino, Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation, Oncogene, vol.29, pp.2449-2456, 2010.

A. Mocsai, J. Ruland, and V. L. Tybulewicz, The SYK tyrosine kinase: a crucial player in diverse biological functions, Nat Rev Immunol, vol.10, pp.387-402, 2010.

V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley et al., Epigenetic silencing of novel tumor suppressors in malignant melanoma, Cancer Res, vol.66, pp.11187-11193, 2006.

M. Narita, V. Krizhanovsky, S. Nunez, A. Chicas, S. A. Hearn et al., A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation, Cell, vol.126, pp.503-514, 2006.

S. C. Naumann, W. P. Roos, E. Jost, C. Belohlavek, V. Lennerz et al., Temozolomide-and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53, Br J Cancer, vol.100, pp.322-333, 2009.

R. M. Nazarian, V. G. Prieto, D. E. Elder, and L. M. Duncan, Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study, J Cutan Pathol, vol.37, 2010.

C. Nogueira, K. H. Kim, H. Sung, K. H. Paraiso, J. H. Dannenberg et al., Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis, Oncogene, 2010.

A. F. Olumi, G. D. Grossfeld, S. W. Hayward, P. R. Carroll, T. D. Tlsty et al.,

, Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, Cancer Res, vol.59, pp.5002-5011

V. E. Papaioannou, T-box genes in development: from hydra to humans, Int Rev Cytol, vol.207, pp.1-70, 2001.

J. F. Passos, G. Nelson, C. Wang, T. Richter, C. Simillion et al., Feedback between p21 and reactive oxygen production is necessary for cell senescence, Mol Syst Biol, vol.6, p.347, 2010.

E. E. Patton, H. R. Widlund, J. L. Kutok, K. R. Kopani, J. F. Amatruda et al.,

S. Berghmans, E. A. Mayhall, D. Traver, and C. D. Fletcher, BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma, 2005.

, Curr Biol, vol.15, pp.249-254

S. Pelengaris, M. Khan, E. , and G. , c-MYC: more than just a matter of life and death, Nat Rev Cancer, vol.2, pp.764-776, 2002.

C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini et al., Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity, Cancer Res, vol.66, pp.6503-6511, 2006.

J. Pomerantz, N. Schreiber-agus, N. J. Liegeois, A. Silverman, L. Alland et al., The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53, Cell, vol.92, pp.713-723, 1998.

J. N. Poynter, J. T. Elder, D. R. Fullen, R. P. Nair, M. S. Soengas et al., BRAF and NRAS mutations in melanoma and melanocytic nevi, Melanoma Res, vol.16, pp.267-273, 2006.

S. Prince, S. Carreira, K. W. Vance, A. Abrahams, C. R. Goding et al., Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization, Cancer Res Sage, vol.14, pp.3037-3050, 2000.

C. J. Sarkisian, B. A. Keister, D. B. Stairs, R. B. Boxer, S. E. Moody et al., Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis, Nat Cell Biol, vol.9, pp.493-505, 2007.

E. R. Sauter, U. C. Yeo, A. Von-stemm, W. Zhu, S. Litwin et al., Cyclin D1 is a candidate oncogene in cutaneous melanoma, Cancer Res, vol.62, pp.3200-3206, 2002.

C. A. Schmitt, J. S. Fridman, M. Yang, S. Lee, E. Baranov et al., A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy, Cell, vol.109, pp.335-346, 2002.

D. J. Schwahn, N. A. Timchenko, S. Shibahara, and E. E. Medrano, Dynamic regulation of the human dopachrome tautomerase promoter by MITF, ER-alpha and chromatin remodelers during proliferation and senescence of human melanocytes, Pigment Cell Res, vol.18, pp.203-213, 2005.

N. E. Sharpless, M. R. Ramsey, P. Balasubramanian, D. H. Castrillon, and R. A. Depinho, The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis, Oncogene, vol.23, pp.379-385, 2004.

K. S. Smalley, M. Lioni, M. Dalla-palma, M. Xiao, B. Desai et al., Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas, Mol Cancer Ther, vol.7, pp.2876-2883, 2008.

L. M. Soares, K. Zanier, C. Mackereth, M. Sattler, and J. Valcarcel, Intron removal requires proofreading of U2AF/3' splice site recognition by DEK, Science, vol.312, pp.1961-1965, 2006.

M. S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller et al., Inactivation of the apoptosis effector Apaf-1 in malignant melanoma, Nature, vol.409, pp.207-211, 2001.

M. S. Soengas and S. W. Lowe, Apoptosis and melanoma chemoresistance, Oncogene, vol.22, pp.3138-3151, 2003.

R. Sotillo, P. Dubus, J. Martin, E. De-la-cueva, S. Ortega et al., Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors, Embo J, vol.20, pp.6637-6647, 2001.

N. Soufir, M. F. Avril, A. Chompret, F. Demenais, J. Bombled et al., Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group, Hum Mol Genet, vol.7, pp.209-216, 1998.

S. Steinert, J. W. Shay, and W. E. Wright, Transient expression of human telomerase extends the life span of normal human fibroblasts, Biochem Biophys Res Commun, vol.273, pp.1095-1098, 2000.

T. Strub, S. Giuliano, T. Ye, C. Bonet, C. Keime et al., Essential role of Microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma, Oncogene, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02530755

E. V. Sviderskaya, V. C. Gray-schopfer, S. P. Hill, N. P. Smit, T. J. Evans-whipp et al.,

L. Hill, V. Bataille, G. Peters, and D. Kipling, p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression, J Natl Cancer Inst, vol.95, pp.723-732, 2003.

E. V. Sviderskaya, S. P. Hill, T. J. Evans-whipp, L. Chin, S. J. Orlow et al., p16(Ink4a) in melanocyte senescence and differentiation, J Natl Cancer Inst, vol.94, pp.446-454, 2002.

T. Waldmann, I. Scholten, F. Kappes, H. G. Hu, and R. Knippers, The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin, Gene, vol.343, pp.1-9, 2004.

S. Wang, Y. B. Ding, G. Y. Chen, J. G. Xia, and Z. Y. Wu, Hypermethylation of Syk gene in promoter region associated with oncogenesis and metastasis of gastric carcinoma, World J Gastroenterol, vol.10, pp.1815-1818, 2004.

C. Wellbrock, S. Rana, H. Paterson, H. Pickersgill, T. Brummelkamp et al.,

, Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF, PLoS One, vol.3, 2734.

C. Wellbrock and M. Schartl, Multiple binding sites in the growth factor receptor Xmrk mediate binding to p59fyn, GRB2 and Shc, Eur J Biochem, vol.260, pp.275-283, 1999.

D. Willis-martinez, H. W. Richards, N. A. Timchenko, and E. E. Medrano, Role of HDAC1 in senescence, aging, and cancer, Exp Gerontol, vol.45, pp.279-285, 2010.

T. M. Wise-draper, H. V. Allen, E. E. Jones, K. B. Habash, H. Matsuo et al., Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions, Mol Cell Biol, vol.26, pp.7506-7519, 2006.

T. M. Wise-draper, H. V. Allen, M. N. Thobe, E. E. Jones, K. B. Habash et al., The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7, J Virol, vol.79, pp.14309-14317, 2005.

O. Witt, H. E. Deubzer, T. Milde, and I. Oehme, HDAC family: What are the cancer relevant targets?, Cancer Lett, vol.277, pp.8-21, 2009.

C. H. Wu, J. Van-riggelen, A. Yetil, A. C. Fan, P. Bachireddy et al., , 2007.

, Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation, Proc Natl Acad Sci U S A, vol.104, pp.13028-13033

Q. Wu, Z. Li, H. Lin, L. Han, S. Liu et al., DEK overexpression in uterine cervical cancers, Pathol Int, vol.58, pp.378-382, 2008.

W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando et al., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, vol.445, pp.656-660, 2007.

W. Yarosh, T. Barrientos, T. Esmailpour, L. Lin, P. M. Carpenter et al., TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases, Cancer Res, vol.68, pp.693-699, 2008.

E. J. Yeo, Y. C. Hwang, C. M. Kang, H. E. Choy, and S. C. Park, Reduction of UVinduced cell death in the human senescent fibroblasts, Mol Cells, vol.10, pp.415-422, 2000.

M. J. You, D. H. Castrillon, B. C. Bastian, R. C. O'hagan, M. W. Bosenberg et al., Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice, Proc Natl Acad Sci U S A, vol.99, pp.1455-1460, 2002.

A. Zaky, C. Busso, T. Izumi, R. Chattopadhyay, A. Bassiouny et al., Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage, Nucleic Acids Res, vol.36, pp.1555-1566, 2008.

S. Zhang, Y. , and D. , PI(3)king apart PTEN's role in cancer, Clin Cancer Res, vol.16, pp.4325-4330, 2010.

Y. Zhang, Y. Xiong, and W. G. Yarbrough, ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways, Cell, vol.92, pp.725-734, 1998.

J. Zhu, J. Blenis, and J. Yuan, Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1, Proc Natl Acad Sci U S A, vol.105, pp.6584-6589, 2008.

S. Zhu, H. Wurdak, Y. Wang, A. Galkin, H. Tao et al., A genomic screen identifies TYRO3 as a MITF regulator in melanoma, Proc Natl Acad Sci U S A, vol.106, pp.17025-17030, 2009.

D. Zhuang, S. Mannava, V. Grachtchouk, W. H. Tang, S. Patil et al.,

A. E. Berman, T. J. Giordano, E. V. Prochownik, and M. S. Soengas, , 2008.

L. Zuo, J. Weger, Q. Yang, A. M. Goldstein, M. A. Tucker et al., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma, Nat Genet, vol.12, pp.97-99, 1996.

D. Zyss, P. Montcourrier, B. Vidal, C. Anguille, F. Merezegue et al., The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression, Cancer Res, vol.65, pp.10872-10880, 2005.